Page 95 - ITPS-8-1

INNOSC Theranostics and
Pharmacological Sciences Brain glutamate level after treatment with NAC

doi: 10.1016/j.pnpbp.2006.03.034 doi: 10.1007/s40263-015-0272-9
42. Tenório MCD, Graciliano NG, Moura FA, de Oliveira ACM, 52. Afshar H, Roohafza H, Mohammad-Beigi H, et al.
Goulart MOF. N-Acetylcysteine (NAC): Impacts on human N-acetylcysteine add-on treatment in refractory obsessive-
health. Antioxidants (Basel). 2021;10(6):967. compulsive disorder: A randomized, double-blind, placebo-
controlled trial. J Clin Psychopharmacol. 2012;32(6):797-803.
doi: 10.3390/antiox10060967
doi: 10.1097/JCP.0b013e318272677d
43. Raghu G, Berk M, Campochiaro PA, et al. The multifaceted
therapeutic role of N-acetylcysteine (NAC) in disorders 53. Yazici KU, Percinel I. N-acetylcysteine augmentation
characterized by oxidative stress. Curr Neuropharmacol. in children and adolescents diagnosed with treatment-
2021;19(8):1202-1224. resistant obsessive-compulsive disorder: Case series. J Clin
Psychopharmacol. 2015;35(4):486-489.
doi: 10.2174/1570159X19666201230144109
doi: 10.1097/JCP.0000000000000362
44. Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry:
Current therapeutic evidence and potential mechanisms of 54. Lafleur DL, Pittenger C, Kelmendi B, et al. N-acetylcysteine
action. J Psychiatry Neurosci. 2011;36(2):78-86. augmentation in serotonin reuptake inhibitor refractory
obsessive-compulsive disorder. Psychopharmacology (Berl).
doi: 10.1503/jpn.100057 2006;184(2):254-256.
45. Baxter PS, Bell KF, Hasel P, et al. Synaptic NMDA receptor doi: 10.1007/s00213-005-0246-6
activity is coupled to the transcriptional control of the
glutathione system. Nat Commun. 2015;6:6761. 55. Yolland CO, Hanratty D, Neill E, et al. Meta-analysis of
randomised controlled trials with N-acetylcysteine in
doi: 10.1038/ncomms7761 the treatment of schizophrenia. Aust N Z J Psychiatry.
46. Sarris J, Byrne G, Castle D, et al. N-acetyl cysteine (NAC) 2020;54(5):453-466.
augmentation in the treatment of obsessive-compulsive doi: 10.1177/0004867419893439
disorder: A phase III, 20-week, double-blind, randomized,
placebo-controlled trial. Prog Neuropsychopharmacol Biol 56. Bhaskara S. N-Acetylcysteine augmentation in refractory
Psychiatry. 2022;117:110550. obsessive-compulsive disorder. J Psychiatry Neurosci.
2019;44(3):215-216.
doi: 10.1016/j.pnpbp.2022.110550
doi: 10.1503/jpn.180179
47. Li F, Welling MC, Johnson JA, et al. N-acetylcysteine for
pediatric obsessive-compulsive disorder: A small pilot 57. Goodman WK, Price LH, Rasmussen SA, et al. The yale-
study. J Child Adolesc Psychopharmacol. 2020;30(1):32-37. brown obsessive compulsive scale. I. Development, use, and
reliability. Arch Gen Psychiatry. 1989;46(11):1006-1011.
doi: 10.1089/cap.2019.0041
doi: 10.1001/archpsyc.1989.01810110048007
48. Ghanizadeh A, Mohammadi MR, Bahraini S, Keshavarzi Z,
Firoozabadi A, Alavi Shoshtari A. Efficacy of N-acetylcysteine 58. Saxena S, Bota RG, Brody AL. Brain-behavior relationships in
augmentation on obsessive compulsive disorder: obsessive-compulsive disorder. Semin Clin Neuropsychiatry.
A multicenter randomized double blind placebo controlled 2001;6(2):82-101.
clinical trial. Iran J Psychiatry. 2017;12(2):134-141. doi: 10.1053/scnp.2001.21833
49. Costa DLC, Diniz JB, Requena G, et al. Randomized, 59. Moran MM, McFarland K, Melendez RI, Kalivas PW,
double-blind, placebo-controlled trial of N-acetylcysteine Seamans JK. Cystine/glutamate exchange regulates
augmentation for treatment-resistant obsessive-compulsive metabotropic glutamate receptor presynaptic inhibition of
disorder. J Clin Psychiatry. 2017;78(7):e766-e773. excitatory transmission and vulnerability to cocaine seeking.
doi: 10.4088/JCP.16m11101 J Neurosci. 2005;25(27):6389-6393.
50. Paydary K, Akamaloo A, Ahmadipour A, Pishgar F, doi: 10.1523/JNEUROSCI.1007-05.2005
Emamzadehfard S, Akhondzadeh S. N-acetylcysteine 60. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric
augmentation therapy for moderate-to-severe obsessive- disorders: Evidence base and therapeutic implications. Int J
compulsive disorder: Randomized, double-blind, placebo- Neuropsychopharmacol. 2008;11(6):851-876.
controlled trial. J Clin Pharm Ther. 2016;41(2):214-219.
doi: 10.1017/S1461145707008401
doi: 10.1111/jcpt.12370
61. Farokhnia M, Azarkolah A, Adinehfar F, et al.
51. Sarris J, Oliver G, Camfield DA, et al. N-Acetyl Cysteine N-acetylcysteine as an adjunct to risperidone for treatment of
(NAC) in the treatment of obsessive-compulsive disorder: negative symptoms in patients with chronic schizophrenia:
A 16-week, double-blind, randomised, placebo-controlled A randomized, double-blind, placebo-controlled study. Clin
study. CNS Drugs. 2015;29(9):801-809. Neuropharmacol. 2013;36(6):185-192.

Volume 8 Issue 1 (2025) 89 doi: 10.36922/itps.4887